Home | Publications | Finance / Investment place holder
place holder place holder

Finance / Investment

Financial Markets Research: ASCO Review Part IICO 2006 Annual Meeting

A summary of highlights presented at the ASCO 2006 Annual Meeting

Publication Date   August 2006
Publisher   Datamonitor
Product Type   Strategic Report
Pages   10
ISBN Number   not applicable
Product Code   DAT543
Ask a question about this product?

Price £2,195.00

approximately: $4,347 | €2,790

Summary


Introduction

ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor's comments on the most important events at the 2006 conference.

Highlights

GlaxoSmithKline's lapatinib should represent a new standard of care for patients for HER2+ metastatic breast cancer patients that have progressed after Herceptin. Furthermore, the strength of lapatinib in a post-Herceptin setting supports the development of this drug in earlier settings.Following dasatinib's favorable review by an FDA panel, we believe data presented at ASCO is likely to have a very positive impact on the rate of uptake of dasatinib.Advantage in the renal cell carcinoma market has shifted to PFE's Sutent after data comparing BAY/ONXX's Nexavar to interferon in the front-line setting was not ready to be presented, thus opening the door for Sutent.

Scope

  • Provides a summary of highlights presented at ASCO 2006 on Friday June 2, 2006 through Sunday June 4, 2006h3>
  • Drugs covered include Amgen's denosumab (AMG-162), AstraZeneca's Zactima (vandetanib/ZD6474), and Bristol-Myers Squibb's Sprycel (dasatinib)h3>

Reasons to Purchase

  • Identify the most important events that occurred at ASCO 2006h3>
  • Understand the impact of key data presentations on the potential future dynamics of the oncology market

Content


  • Renal cell carcinoma and multiple myeloma: leaders emerge, but plenty of room for numerous competitors
  • Asco Coverage
  • Key highlights
  • Highlights In Renal Cell Carcinoma
  • Focus on renal cell carcinoma continues at ASCO
  • Sequential targeted therapy looks promising, but case against EGFR inhibition builds
  • Reports of"failure" are misleading, but Nexavar yet to prove survival benefit
  • Renal cell summary: Sutent and temsirolimus step forward while Nexavar stands still
  • Highlights In Multiple Myeloma
  • Three agents offer significant clinical benefit
  • Thalomid-containing regimens now have time to progression and survival benefit data
  • Thalomid data in newly diagnosed elderly patients impressive but unlikely to have major impact on treatment
  • Median overall survival for Revlimid in relapsed and refractory disease recently reached
  • Uncertainty surrounds Revlimid's efficacy in Thalomid failures
  • With risk factors for thromboembolism identified, Revlimid can be used more safely
  • Optimal treatment algorithm remains undetermined - which treatment will be used upfront?
  • Appendix
    • Datamonitor Healthcare
    • Disclosure information
    • Ask the analyst